Fig.5 TRPA1 deficiency reduces macrophage infiltration in lesions.
(A) The expression of F4/80, iNOS, CD206 and Gapdh using Western blot.
(B) Immunofluorescence staining images of F4/80 (red) and DAPI (blue;
×40.
3.5 Administration TRPA1 antagonists HC030031 mitigates skin
inflammation andscratching
behavior in DNCB-induced AD mouse model
To eliminate the possibility of compensatory mechanisms in the KO
animals and explore whether selective TRPA1 antagonists HC030031 can be
used as a targeted therapy for DNCB-induced AD. Experiments
were carried out involving
pre-treatment with the HC030031.
Wild-type (WT) mice received an intraperitoneal injection of HC-030031
(TRPA1 receptor analog, 100mg/kg,
ApexBio, USA). Applying HC-030031
prior to DNCB challenge alleviated atopic symptoms, ear thickness and
scratching behavior (Figure 6A-6C ). At the same time, HC-030031
recovered histological abnormalities (Figure 6D-6E). Our experiments
with TRPA1 antagonists were similar to the observed profile in TRPA1 KO
mice. Altogether, the obtained results show that anti-TRPA1 represents a
potential therapeutic target for AD disease.